Death of a patient with Leukemia exposes delays in the supply of oncology medication from the SUS

Larissa Amorim, 33 years old, died without receiving a medicine considered essential against the leukemia that affected her. The therapy had already undergone technical evaluation by the federal government and was part of the public oncological care policies of Sistema Único and Saúde (SUS). The family even had a court decision that determined the immediate supply of the drug to the patient. Contudo, between Justiça’s order and Larissa’s death, 59 days passed. Ela left two children.
SUS structural Atraso is reported to the PGR
The case of Larissa Amorim is not isolated in the Brazilian public health scenario. Associação Brasileira of Câncer of Sangue (Abrale) filed a representation in Procuradoria-General of República (PGR). The entity requests an in-depth investigation into what it classifies as a structural non-compliance with the oncology pharmaceutical assistance policy in the country. Terapias that have already been officially incorporated into the SUS remain out of reach for a significant portion of patients for months and, in some cases, for years after their approval.
Abrale actively monitors 185 patients who face difficulties accessing treatments already incorporated into the system. In 2025, almost half of the consultations provided by its socio-legal service – precisely 46.49% – were related to problems accessing treatment. Destes, 85% were SUS users. Mais than a quarter of these cases resulted in lawsuits. The association monitors at least 64 processes linked to these access barriers, demonstrating the persistence and scope of the problem.
Prazo legal for remedy incorporation fails
The incorporation of a drug into Sistema Único of Saúde is often seen as the end of a long and complex process. In reality, it only marks the end of the scientific evaluation. Antes before being made available on the public network, a therapy is subjected to rigorous analyzes of efficacy, safety, cost-benefit and budgetary impact, conducted by Comissão Nacional of Incorporação of Tecnologias in the SUS (Conitec). Somente After this step, Ministério of Saúde formalizes the inclusion of the medicine in health policies.
The legislation establishes a maximum period of 180 days for public authorities to organize purchases, define usage protocols, structure distribution and prepare the service network. In cases of cancer, this deadline should be a priority, according to the change introduced in Lei Orgânica from Saúde in 2023. Entretanto, patient organizations state that it is precisely in this interval that many essential treatments become stagnant. Abrale’s Políticas Públicas and Advocacy manager, Luana Ferreira Lima, explains that the delays center on defining responsibilities. Isso includes who makes the purchase, how the financing is done and the distribution method, whether it is centralized by Ministério of Saúde or by the states.
- Definição from Responsabilidade:Questões about who purchases the medicine.
- Financiamento:Desafios in resource allocation and release.
- Logística from Distribuição:Falhas in delivery and access to patients.
- Protocolos Internos:Burocracia in operationalization.
Luana Ferreira Lima notes that “the patient would, theoretically, have to have access to the medicine within a period of 180 days. But this period ends, and he does not receive the medicine, due to bureaucratic, operational, coordination and resource issues”. The concrete result of this situation is that patients wait for medicines whose benefit has already been officially recognized by Estado itself. The Abrale representative reinforces the seriousness: “There are patients dying before receiving medications to which they are already entitled.” Alguns cases far exceed the legal deadline. Pacientes still report difficulties in obtaining the immunotherapy drug brentuximab, for example, which was incorporated into the SUS in 2019.
Impacto waiting for cancer treatment
Para patients dealing with rapidly evolving oncological diseases, waiting for a medicine is not merely a bureaucratic issue; it directly alters the course of the disease. Blinatumomab, the drug that Larissa Amorim was waiting for, is an immunotherapy that works by stimulating the immune system to attack leukemic cells that have the CD19 protein. Este treatment represents a significant advance in the fight against acute lymphoblastic leukemia, especially in situations where the disease returns after initial control or does not respond to conventional chemotherapy.
Esses are the most challenging conditions, in which traditional therapies have already proven ineffective. The onco-hematologist and deputy director of BP – Beneficência Portuguesa of São Paulo, Breno Gusmão, highlights the importance of this type of medicine as a “therapeutic opportunity within a clinical moment that is being experienced”. Hematologist Indianara Brandão, from Faculdade and Medicina from ABC, adds that drugs such as blinatumomab work as rescue therapies and serve as a bridge to bone marrow transplantation. Esses medications are a specific strategy designed for an exact moment in the disease. Quando this moment passes, the opportunity for treatment may be irreversibly lost.
The delay in the administration of such therapies, according to doctor Indianara Brandão, sets a serious precedent for the uncontrolled progression of the disease. Isso can lead to serious infections, hemorrhages and, consequently, the loss of the clinical conditions necessary for the patient to progress to the next stages of treatment, compromising their recovery.
The case of Larissa Amorim and the drug blinatumomab
Larissa Amorim was diagnosed with chronic myeloid leukemia (CML) as a child, in 2002. Natural from Bahia, began to receive treatment in São Paulo, managing to keep the disease under control for more than two decades. Durante During this period, she used an inhibitor that, for many years, was available through patient support programs. Foi During this period, Larissa built his family, got married and had two children, Benjamin, 8 years old, and Sofia, 7 years old.
Apesar of the battle and legal support to obtain blinatumomab, the medicine never arrived. The system failure cost the patient her life, highlighting the profound gaps between the approval of therapies and their effective delivery to those who urgently need them. Ministério of Saúde, consulted about the situation, claims to have a plan to expand the supply of medicines. Entretanto, the department did not comment directly on compliance with the established legal deadline or on the representation filed with Procuradoria-Geral of República.






